Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma

Trial Profile

Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Sildenafil (Primary) ; Sorafenib (Primary) ; Valproic acid (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 May 2015 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018, as reported by ClinicalTrials.gov.
    • 03 Apr 2013 Planned number of patients changed from 51 to 66 as reported by ClinicalTrials.gov.
    • 03 Apr 2013 Planned initiation date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top